Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC

Incorporating TRT provided significant survival benefits in patients with oligo-organ metastatic NSCLC who received first-line third-generation EGFR TKIs, with acceptable side effects. The administration of higher radiation doses during a phase of tumor shrinkage may be associated with optimal outcomes.

Authors

Hongfu Sun (ORCID: https://orcid.org/0000-0003-3436-7831)
Qiang Cao (ORCID: https://orcid.org/0000-0001-8654-0195)
Baosheng Li (ORCID: https://orcid.org/0000-0002-1515-2918)
Xiaoting Gu (ORCID: https://orcid.org/0000-0001-5832-2078)
Jiaxiao Geng
Yan Yi (ORCID: https://orcid.org/0000-0003-2639-8574)

Institutions

Shandong First Medical University (CN)

Publication Details

Journal: Frontiers in Oncology
Published: 2025-11-26
DOI: https://doi.org/10.3389/fonc.2025.1707876
Primary Topic: Lung Cancer Treatments and Mutations
Type: article
Field-Weighted Citation Impact: 0.00

Controls

|||

ALL TIME

JAN

FEB

MAR

APR

MAY

JUN

JUL

AUG

SEP

OCT

article

Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC

Hongfu Sun, Qiang Cao, Baosheng Li, Xiaoting Gu et al.

Nov 26, 2025

Frontiers in Oncology

Lung Cancer Treatments and Mutations

article

Effect, safety, timing and dose of thoracic radiotherapy plus third-generation EGFR-TKIs as first-line treatment in patients with EGFR-mutated oligo-organ metastatic NSCLC

Hongfu Sun, Qiang Cao, Baosheng Li, Xiaoting Gu, Jiaxiao Geng, Yan Yi

November 26, 2025article en

Abstract

Incorporating TRT provided significant survival benefits in patients with oligo-organ metastatic NSCLC who received first-line third-generation EGFR TKIs, with acceptable side effects. The administration of higher radiation doses during a phase of tumor shrinkage may be associated with optimal outcomes.

Frontiers in OncologyVol. 15

Shandong First Medical University (CN)

Openalex Percentile: Top 46%

Lung Cancer Treatments and Mutations

DOI Open Access PDF OpenAlex

AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.